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1. Introduction 
Huntington's Disease (HD) is an autosomal dominant, neurodegenerative disease. It is 
characterized by severe involuntary motor dysfunction, so-called choreic movements, 
neurological and psychiatric symptoms and cognitive impairments that lead to dementia 
(Bates et al., 2002). Genetic markers for the gene that causes HD were identified in 1983, 
located on the short arm of chromosome four (Gusella et al., 1983). Ten years later in 1993 
the gene was cloned (Huntington’s Disease Collaborative Research Group, 1993). HD was 
thus from the mid-1980s one of the first diseases where it was possible to predict whether an 
asymptomatic individual had inherited the genetic markers and would therefore become ill 
in the future. The clinical diagnosis of HD is based on the presence of motor symptoms and 
a positive mutation analysis, or on neurological and psychiatric symptoms in patients with a 
family history of HD. 
In almost half of HD cases clinical onset is indicated with psychiatric symptoms such as 
depression, anxiety and aggressive outbursts (Close Kirkwood et al., 2002a; Julien et al., 
2007; van Duijn et al., 2007). Sometimes onset of the disease presents with schizophrenic or 
manic-like symptoms (Julien et al., 2007; Shiwach, 1994). However, the initial indication of 
onset is often in the form of subtle cognitive impairment before manifest neurological or 
psychiatric symptoms occur. All patients become demented over the course of the disease 
(Brandt et al., 1984). The first symptoms occur most frequently in the 45 to 50 age bracket, 
although age of onset ranges from 2 to 80 years (Roos et al., 1991). The average life 
expectancy after clinical onset is 15-17 years (Roos et al., 1993). In the juvenile form of 
Huntington’s Disease onset occurs before age 20 (5-10% of cases) and approximately 25% of 
HD debuts after age 50, some at age 70 or older (Kremer, 2002). There is currently no specific 
treatment to cure or delay the disease. 
2. General aspects of the disease 
2.1 Nomenclature 
Huntington’s Disease has been described in varying ways throughout history. Christian 
Lund described HD or Anundsjö disease in Norwegian in 1860 (Orbeck, 1960) and a young 
American doctor, George Huntington, published a description of HD in 1872 which is still 
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largely valid (Huntington, 1872). The disease has since carried his name and is also called 
Huntington's Chorea (from the Greek, χοǒόǓ, dance and khoreia, chorea). The Westphal 
variant of Huntington’s Disease manifests in muscular rigidity and hypokinesia in young 
adults, usually between 20-30 years. The correct term today is Huntington’s Disease. 
2.2 Prevalence 
The prevalence of HD in many countries is not established and estimates differ considerably 
from country to country (Harper, 2002). The prevalence in Western Europe is estimated at 
approximately 3-7 per 100 000 depending on city and country. For example, the prevalence 
is well mapped in England and varies in the range 2.5-9.95 per 100 000 (Harper, 2002). North 
American prevalence is estimated at 4.1 to 8.4 per 100,000 inhabitants. Many countries have 
no information or only sporadic information on the prevalence of HD. The prevalence is 
lower among indigenous populations in Africa (e.g. 0.01 per 100 000 in South Africa) and 
Asia (0.7 per 100 000 in Japan and 0.4 per 100 000 in Hong Kong). Areas with notably high 
prevalence of HD are found in Tasmania, Australia (17:100 000) (Conneally, 1984) and in the 
Lake Maracaibo district of Venezuela (Young et al., 1986). 
2.3 Cause and heredity 
HD (OMIM 143100) is an autosomal dominant neurodegenerative disease caused by a 
mutation in the short arm of chromosome 4 (4p16.3) (Gusella et al., 1983) (Figure 1).  
 
Fig. 1. Autosomal dominant inheritance 
2.4 CAG sequences 
A mutation in the huntingtin (HTT) gene causes an increase in the number of trinucleotide 
CAG (Cytosine, Adenosine, Guanine) repetitions, always 36 or more for individuals with 
HD (Huntington’s Disease Collaborative Research Group, 1993). A person with normal 
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function has between 9 and 35 repetitions of the CAG sequence. Repetitions from 36 to 39 
are characterized by reduced penetrance, therefore an individual in this range will not 
automatically develop the characteristic symptoms of HD during his lifetime, but children 
of such an individual are still at risk (Rubinsztein et al., 1996). A sequence of 40 CAG 
repetitions or more has full penetrance. There is also a negative correlation between the 
number of CAG repetitions and age at onset, but this does not explain all variation in the 
age at onset, which means that other factors possibly interact and determine when disease 
symptoms will appear (see table 1).  
CAG 
sequences 
 
≤ 28 Normal function
29-35 The individual will not develop HD, but the next generation inherits 
the risk of developing the disease.
36-39 Reduced penetrance; some individuals will develop HD and 
development is generally late in life. The next generation inherits the 
risk of developing the disease. A number of non-symptomatic cases in 
older individuals with 36-39 CAG sequences have been reported. 
≥ 40 Full penetrance; all individuals will develop the disease. Higher CAG 
sequences provides earlier disease onset (negative correlation). Juvenile 
HD manifests itself most often in people with ≥ 60 CAG repetitions. 
Table 1. Number of CAG sequences and risk of onset. 
The number of CAG repetitions tends to be extended at the formation of the sex cells and 
takes place primarily when the gene is inherited from the father (Kehoe et al., 1999). 
Inheritance via the male line leads to cases of earlier onset and also more deleterious disease 
outcome, so called anticipation (Ridley et al., 1988). Estimated age at onset can be calculated 
using a regression equation, although not always accurately (Langbehn et al., 2004; 
Langbehn et al., 2009; Rubinsztein et al., 1997). Spontaneous mutations are very rare and 
explain only 0.1 % of the cases of the disease. However, it is reported that about 8% of HD 
patients do not have an affected family member (Almqvist et al., 2001; Siesling et al., 2000). 
2.5 Neuropathological changes 
A widespread, selective neuropathology is found in HD, with cell loss and atrophy. The 
changes are strikingly selective in their effect on specific brain cell types and particular brain 
structures. Medium γ-aminobutyric acid (GABA) spiny neurons are the neuronal cells 
primarily affected, mainly in the caudate nucleus and putamen. The cortex is less affected 
and the cerebellum is relatively spared. The HD gene product, a very large 350 kDa protein, 
termed huntingtin, is believed to have a toxic effect which leads to cellular dysfunction and 
eventual death of neurons (Huntington’s Disease Collaborative Research Group, 1993). The 
exact mechanism of the toxic effect is still poorly understood. Early neuropathological 
changes are seen selectively in the striatum, where 90% of neuronal cells are medium spiny 
projection neurons (MSP neurons). Loss of projection neurons in the caudate nucleus is the 
dominant neuropathological change. Death of neuronal cells continues gradually in layers 3, 
5 and 6 of the cortex, the substantia nigra and the CA1 region of the hippocampus. Loss of 
enkephalin-withholding MSP neurons in the striatum, which indirectly controls voluntary 
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and related movements, constitutes the neurobiological basis for HD chorea. The 
preferential involvement of the indirect pathway of basal ganglia-thalamocortical circuitry is 
believed to be the cause of chorea (Paulsen et al., 2005a). Fronto-striatal circuitry linking the 
striatum with frontal lobes is also affected. In addition, changes in the substantia nigra, 
hippocampus, hypothalamus and selectively in the cortex and white matter are found. 
2.6 Chemical changes 
Profound atrophy in large parts of the brain is seen in the final stage of the disease. 
Neuronal loss leads to reduction of neurotransmitters such as γ-aminobutyric acid (GABA), 
glutamate, glutamic acid decarboxylase (GAD), peptides (e.g. enkephalin) and acetylcholine 
(choline acetyltransferase, ChAT) in the striatum. On the other hand, there are increases in 
serotonin levels, while serotonin receptor density decreases. A reduction in postsynaptic D1 
and D2 dopamine receptors and in the dopamine transporter DAT in the striatum also has 
the potential to explain the cognitive impairments of HD patients (Antonini et al., 1996; 
Backman et al., 1997). The complex and multifarious symptoms of HD have been attributed 
to these neuropathological and neurochemical changes (Walker, 2007). 
3. Clinical picture and progress 
3.1 Clinical picture 
The clinical picture includes severe motor dysfunction, cognitive decline leading to 
dementia and neurological and psychiatric symptoms. Symptoms of HD vary from patient 
to patient and although all symptoms may be present, some symptoms are more dominant 
during different phases. Cognitive impairments occur early in the disease, exacerbated 
when manifest disease progresses and causes reductions in everyday functions. Affected 
cognitive domains include psychomotor speed, language, memory and executive functions; 
and later in the disease visuospatial abilities are also affected (Robins Wahlin et al., 2010; 
Robins Wahlin et al., 2007). 
3.2 Motor symptoms 
Severe locomotor dysfunction with hyperkinesia characterizes HD. These involuntary 
movements are seen first in the fingers and toes, then in the trunk. Approximately 10% of all 
patients with HD may, however, have the juvenile onset or Westphal variant of HD with 
symptoms of hypokinesia and rigidity similar to Parkinson's disease (Bittenbender & 
Quadfasel, 1962; Bruyn, 1962). Difficulties with balance occur, with exaggerated, fidgeting 
motor action and a tendency to violent involuntary movements. HD patients often walk 
with a dance-like gait with legs widely separated to compensate for the lack of balance and 
control. The symptoms may cause the patient to appear to be intoxicated by alcohol. Almost 
all patients manifest irregularly timed, randomly distributed and abrupt choreatic 
movements (Barbeau et al., 1981). They may keep their hands in their pockets to limit 
uncontrollable arm actions. Facial musculature is also affected with characteristic chorea of 
the face showing in the form of pouting of the lips, lifting of the eyebrows, frowning and 
nodding head movements. Eye movements become disturbed at an early stage, with jerky 
action and the patient has difficulty focusing the eyes on moving objects. Fine motor skills 
decline, characterized by clumsiness and problems with grasping and holding objects. A 
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patient may be diagnosed when subtle neurologic symptoms are identifiable as disturbed 
tongue and eye movements. Dysarthria is found early, while dysphasia is common in the 
final stage. For about half of patients the extrapyramidal motor symptoms manifest at 
clinical onset (Mattsson, 1974). Patients with later age of onset, 50-70 years of age, debut 
with involuntary movements, walking difficulties and dysphasia. These patients usually 
have a slower and more benign development of the pathological processes compared with 
patients with a younger age of onset (see Table 2). 
Prodromal phase —  
Early Signs  
Manifest and clinical phase --  
Signs & symptoms  
Dementia Phase -- 
Late in the disease 
  
Agitation 
Egocentricity, 
persistence 
Myotonic dystrophy
Myoclonus 
Problems initiating movements 
Rigidity 
Decreasing involuntary 
movements 
Irritability, 
aggressiveness, anger 
Increasing involuntary 
movements  
Grave or diminishing 
chorea 
Apathy Choreatic manifestations; 
writhing, jerky movements
Increase in falls 
Anxiety Balance and gait difficulty Inability to walk 
Uninhibited behaviour Problems with fine motor skills 
(such as shoe-laces) 
Developmental Dyspraxia 
Impaired impulse 
control 
Problem with swallowing; 
danger of inhalation  
Dysphagia
Euphoria Slowed voluntary movements Bradykinesia
Abnormal eye 
movements 
Inability to control the speed and 
force of movements, clumsiness
Difficulty in swallowing & 
eating 
Sadness Dyskinesia Neglected nutrition 
Depression General weakness Wheelchair bound 
Suicidal Ideation Weight loss Weight loss
Slowness of speech Speech impairments; slurred 
speech & phonological 
impairment, difficulty with 
pronunciation  
Dysphasia, serious speech 
impairments, mutism 
Motion  Problems with daily living 
activities (ADL)
Inability to manage ADL 
Psychological denial Muscle stiffness Incontinence
Symptom searching 
(mutation carriers) 
Delusions, hallucinations Evident regression 
Table 2. Clinical signs and symptoms. 
3.3 Behavioural changes and psychiatric disorders 
About half of patients debut with affective disorders or psychiatric symptoms (Mattsson, 
1974). These may occur before other clear symptoms manifest and can be very difficult to 
manage. They sometimes dominate the clinical picture. Around 72-98% of HD individuals 
develop significant neuropsychiatric problems, including both affective psychoses and non-
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affective psychoses (Mendez, 1994; Paulsen et al., 2001; van Duijn et al., 2007). Major 
depression (Larsson et al., 2006) and manic episodes also occur (van Duijn et al., 2008). In 
the manic phase, presentation is the same as for bipolar disorder. As Huntington noted, 
socially deviant behavior occurs when the individual fails to recognize or register their 
divergent behavior (Huntington, 1872). Hallucinations of hearing, smell, sight, taste and 
touch may be present in HD. The most common neuropsychiatric symptoms are reported to 
be dysphoria (69%), agitation (67%), irritability (65%), apathy (56%), anxiety (52%), 
disinhibition (35%) and euphoria (31%) (Paulsen et al., 2001). The unusually diverse 
manifestations of the disease have made diagnosis difficult to determine, especially before 
DNA testing (Tost et al., 2004)(see Table 2). 
3.4 Depression 
General sadness, depression and anxiety are frequently displayed early in the disease course 
(Larsson et al., 2006). Apathy and irritability (33% to 76%) are also amongst the first 
symptoms (van Duijn et al., 2007). When depression occurs it is often characterized by 
hopelessness, guilt and shame (Baudic et al., 2006; Kessler, 1987). The suicide rate in people 
with HD is twice that of the normal population (Robins Wahlin et al., 2000) and suicide risk 
is highest in the context of disease onset (Paulsen et al., 2005b). It is not known whether 
depression is an integral part of the disease or a response to the knowledge of the severity of 
the disease in the patient’s future, or possibly a combination of the two. The affective 
disorder may be an explicit manifestation of brain damage. Depression can also be an 
expression of grief and anxiety, as HD patients are aware that their children may await the 
same fate that they are facing (Bird, 1999; Paulsen et al., 2001).  
3.5 Cognitive impairments and dementia 
The cognitive symptoms of HD vary from patient to patient and although several symptoms 
can be present, some dominate more than others through the different phases (see Table 3). 
Cognitive signs manifest early in the disease, exacerbated when manifest disease progresses 
causing reduced ability to perform everyday functions. Affected cognitive domains include 
psychomotor speed, language, memory, executive functions and later also visuospatial 
abilities (Lawrence et al., 2000; Robins Wahlin et al., 2010; Robins Wahlin et al., 2007; 
Snowden et al., 2002; Stout et al., 2011). The cognitive deterioration can be divided into three 
main phases, depending on the disease progress: prodromal phase, clinical phase and 
dementia phase. The cognitive phases are associated with reductions in the total functional 
capacity (Total Functional Capacity scale, TFC) in the areas of occupational activity, 
finances, domestic chores, activities of daily living (ADL) and increasing care needs 
(Beglinger et al., 2010; Paulsen, 2010; Shoulson & Fahn, 1979).  
4. The prodromal phase 
4.1 The prodromal phase and early signs 
Neurological symptoms may not be detected in this phase and therefore it is called the 
prodromal, preclinical or presymptomatic phase. Patients often report memory difficulties, 
concentration and attention problems or psychosomatic symptoms before the disease can be 
diagnosed definitively (Verny et al., 2007). Changes in behavior in relation to either family or 
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friends are very subtle. Increasing difficulty managing emotions sometimes leads to aggressive 
outbursts in surroundings where the outbursts may not seem warranted. These are sometimes 
referred to as “catastrophic reactions” (Almqvist et al., 1999). Patients may seek out physicians 
due to stress or psychosomatic symptoms such as gastrointestinal problems or insomnia, 
which need symptomatic treatment. Difficulties arise in managing tasks at home and work 
and such difficulties are only understood with hindsight after diagnosis. 
Prodromal phase —  
Early signs 
Manifest and clinical phase -
Sign & symptoms 
Dementia Phase -- 
Late in the disease 
Psycho-motor slowness ▼ ▼ Clear psycho-motoric 
slowness ▼ ▼ ▼ 
Impaired cognitive functions ▼ 
▼ ▼ 
Executive functions: 
Concentration ▼ 
Initiation ▼ ▼ 
Attention ▼ 
Flexible thinking ▼ 
Logical thinking ▼ 
Simultaneous capacity▼ 
Judgement▼ 
Executive functions: 
Concentration ▼ ▼ 
Initiation ▼ ▼ ▼ 
Attention ▼ ▼ 
Flexible thinking ▼ ▼ 
Logical thinking ▼ ▼ 
Simultaneous capacity ▼ ▼
Judgement ▼ ▼ 
Executive functions: 
Concentration ▼ ▼ ▼ 
Initiation▼ ▼ ▼ 
Attention ▼ ▼ ▼ 
Flexible thinking ▼ ▼ ▼ 
Logical thinking ▼ ▼ ▼ 
Simultaneous capacity ▼ ▼ ▼ 
Judgement ▼ ▼ ▼ 
Slightly impaired verbal flow ▼ Markedly impaired verbal 
flow ▼ ▼ 
Impaired verbal flow or mutism 
▼ ▼ ▼  
Declining working memory ▼ ▼ Clearly impaired working 
memory ▼ ▼ ▼ 
Greatly impaired working 
memory ▼ ▼ ▼ 
Reductions in episodic memory: 
Encoding▼ 
Retrieval; search strategies▼ 
Learning ▼ ▼ 
Recognition (minor problem) 
Significant reductions in 
episodic memory:  
Encoding ▼ ▼ 
Retrieval; search strategies 
▼ ▼ 
Learning ▼ ▼ ▼ 
Recognition ▼ 
Severe reductions in episodic 
memory:  
Encoding ▼ ▼ ▼ 
Retrieval; search strategies ▼ ▼ 
Learning ▼ ▼ ▼ 
Recognition ▼ ▼ 
Prospective memory difficulties 
(remember appointments) ▼ 
Prospective memory 
difficulties  
(forgets to pay bills) ▼ ▼ 
Inability to access prospective 
memory ▼ ▼ ▼ 
Mild visuospatial difficulties ▼ Notable visuospatial 
difficulties ▼ 
Greatly reduced visuospatial 
ability ▼ ▼  
▼ Mild signs and symptoms; ▼ ▼ Moderate disturbance; ▼ ▼ ▼ Grave disorder 
Table 3. Neuropsychological characteristics in Huntington’s Disease. 
4.2 The prodromal cognitive disorder 
The first cognitive changes occur approximately 12-15 years before clinical (motor) onset of 
the disease (Paulsen et al., 2008; Robins Wahlin et al., 2007; Stout et al., 2011). These 
prodromal changes are characterized by reduced executive functions which present as 
alterations in flexibility, reasoning and verbal fluency (Larsson et al., 2008). Lack of logical 
thinking and difficulties in the skills of decision-making, initiative, attention and planning 
are very early signs (Lemiere et al., 2004; van Walsem et al., 2009). The ability to conduct 
complex reasoning, to perform tasks in sequence and to demonstrate simultaneous capacity 
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(dual tasking) all deteriorate gradually (Stout et al., 2011). Linguistic features work relatively 
well, but syntactic complexity and verbal fluency decrease (Larsson et al., 2008). Working 
memory and attention show early impairments (Verny et al., 2007). Episodic memory 
impairment begins with active learning difficulties and inability to apply effective search 
strategies for information (Montoya et al., 2006a; Solomon et al., 2007; Verny et al., 2007). 
Memory tasks where only recognition is required exhibit better performance, suggesting a 
greater problem with retrieval than with encoding of information. Learning new skills 
becomes more difficult and takes longer (see Figure 2) (van Walsem et al., 2009; Verny et al., 
2007). Reduced learning ability and concentration cause problems in occupational, financial 
and domestic functioning. Mutation carriers in the prodromal phase may need to be referred 
for comprehensive neuropsychological assessment to determine their capacity for 
employment, driving of motor vehicles and decision-making (Beglinger et al., 2010). 
 
Fig. 2. Performance time on the Tower of Hanoi Puzzle Across Huntington’s Disease Groups 
(Robins Wahlin et al., 2007). 
5. Clinical phase 
5.1 Clinical neurological and psychiatric disorder 
In the clinical phase the neurological symptoms emerge, including the involuntary 
movements that are characteristic of HD. Many patients lose weight, despite maintaining or 
sometimes even increasing their food intake. The motor symptoms vary in intensity 
depending on the degree of mental tension and activation. At the beginning of the clinical 
phase the involuntary movements are so subtle that patients do not notice them. Later on, 
usually after about 10 years, the chorea causes grave disability. Over this period there is also 
a marked decline in executive functioning and a diminishing ability to get organized in 
everyday situations (Paulsen, 2010; Paulsen et al., 2001). Thinking skills and social and 
emotional functioning deteriorate. Depression, social isolation and denial of symptoms 
(anosognosia) are characteristic also in this phase. The critical period for suicide is precisely 
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connected with the stage of illness (Paulsen et al., 2005a) when understanding is maintained 
and the disease's debilitating symptoms are seen as a threat for the future. Cognitive 
slowness in combination with reduced attention and failure to notice or correct errors 
eventually cause the patient to lose their driving licence and their employment (Beglinger et 
al., 2010). The behavioral problems lead to increased impulsivity, aggressiveness and 
sometimes even hypersexuality. Marital relationships are commonly strained. 
5.2 Clinical cognitive disorder 
As the disease progresses, neuropsychological skills requiring executive functioning 
deteriorate further, including skills such as concentration, patience and stamina. Reduced 
ability for abstract thinking becomes more apparent and the patient exhibits a greater degree 
of concrete thinking. Judgment, discrimination and ability to plan are increasingly reduced. 
Sometimes the patient becomes apathetic. Their semantic memory is initially only slightly 
reduced (Robins Wahlin et al., 2010) and they continue to recognize close relatives and 
familiar surroundings. On the other hand, episodic and prospective memory decline, for 
example remembering future tasks such as appointments (Lundervold et al., 1994b). 
Working memory continues to deteriorate. Memory deficits consist of a generalized 
impaired ability to learn new information and retrieve old knowledge, in other words 
learning curves show a low, flat line (Butters et al., 1994; Verny et al., 2007). Phonemic and 
semantic fluency becomes decidedly slower (e.g. FAS and categories). Vocabulary decreases, 
the patient becomes taciturn, distinctions in meaning are lost and the patient has difficulty 
keeping up with discussions. Because parietal functions are connected to the striatum, 
visuospatial difficulties are manifested at this stage (Lundervold & Reinvang, 1991). 
Deteriorating visuospatial skills as well as psychomotor slowness create major difficulties and 
patients at this stage are strongly advised not to drive a car. Reductions in visuospatial 
functions can be tapped by missed details and distorted relationships when the patient copies 
shapes (e.g. Rey-Osterrieth Complex Figure, see Figure 3 and 4) (Osterrieth, 1944; Rey, 1941).  
   
Fig. 3. and 4. Examples of organized (left panel) and disorganized (right panel) Rey-Osterrieth 
Complex Figures (ROCF) as copied by mutation carriers of HD. The left ROCF was drawn by 
a female mutation carrier with nine years to estimated disease onset and the ROCF right figure 
was drawn by a female carrier with one year to estimated disease onset, although the latter 
patient had not yet been diagnosed by a neurologist as having manifest HD. 
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6. Dementia phase 
6.1 The neuropsychiatric disorder in dementia phase 
Dementia symptoms in HD differ in part from what is seen in other dementias such as 
Alzheimer's disease in that the three great "As" (Aphasia, Apraxia, Agnosia) do not 
dominate in the early symptomatic stage, however, these symptoms manifest in the 
dementia phase. Increasing dementia expresses in passivity, loss of non-verbal 
communication and increasing apathy. Lack of awareness of loss of ability frequently 
occurs. Patients with HD are extremely slow and restricted in both movement and speech 
during the depressive and apathetic phases (Paulsen et al., 2001). Lack of initiative may 
cause them to cease taking care of their own health and hygiene. The sleep cycle is often 
disturbed, probably because of hypothalamic dysfunction (Soneson et al., 2010). Explosive 
eruptions occur, with emotional lability and even catastrophic reactions requiring extra 
resources from daily caregivers (Almqvist et al., 1999; Decruyenaere et al., 2005). In the final 
stage of the disease, the patient is often bedridden, has lost nearly all functions in everyday 
activities and is in need of 24 hour care (Zakzanis, 1998).  
6.2 Cognitive disturbance in dementia phase 
All intellectual functions are severely reduced in the final stage (Lundervold et al., 1994a; 
Zakzanis, 1998). Inability to mobilize knowledge combined with a lack of motivation 
presents as generalized dementia (Redondo-Verge, 2001). Evidence of general intellectual 
sluggishness and semantic slowness is substantial. It may take up to one minute to express a 
word or idea. As the disease progresses, speech and linguistic ability becomes increasingly 
difficult and eventually the patient may become mute. Severe dementia is dominant in the 
final stage (Zakzanis, 1998). 
6.3 Psychological and practical implications 
HD is often associated with shame and guilt. The disease is viewed as a problematic 
psychiatric disease because early cognitive and psychiatric symptoms produce abnormal 
behavior (Paulsen et al., 2001; Robins Wahlin et al., 2000). Symptoms of chorea (involuntary 
movements) have relatively little impact on the person's functional ability, but unfortunately 
attract attention and often give the wrong impression that the patient is intoxicated. 
Neurological signs such as unsteadiness, grimacing and twitching of the face and symptoms of 
mental illness may be seen as shameful by the victim and his family. Stories about patients 
being hidden, rejected or repudiated exist in many families. Many times the disease is a great 
family secret and associated with a lot of denial (Deckel & Morrison, 1996). There is a fear of 
contracting the disease and its insidious onset leads to intense trawling for early signs which 
can then be interpreted as symptoms that the manifest phase has begun (Robins Wahlin, 2007). 
7. Assessment and diagnosis 
7.1 The neuropsychological assessment 
Verbal episodic memory, working memory, executive function, verbal fluency and 
psychomotor speed should be investigated early in the prodromal phase of HD as 
impairments occur before manifest symptoms are visible (Kirkwood et al., 2000; Verny et al., 
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2007). A simple test battery is recommended that includes tests of a variety of cognitive 
abilities including verbal fluency and memory tasks. The Unified Huntington's Disease 
Rating Scale (UHDRS) is specially developed for HD and contains a brief cognitive test 
battery (Huntington Study Group, 1996). The UHDRS is designed to be administered each 
time the patient comes to follow-up appointments. UHDRS takes approximately 30-45 
minutes to implement and includes the following neuropsychological tests which are 
relatively simple to administer. 
1. Letter Fluency (Phonemic) Controlled Oral Word Association Test (COWAT, FAS) 
2. Dementia Rating Scale 
3. Hopkins Verbal Learning Test (HVLT) 
4. Symbol Digit Modalities Test (Digit Symbol in Wechsler Adult Intelligence Scale, WAIS). 
5. Stroop Test.  
(a) Colour Naming 
(b) Word Reading 
(c) Interference 
6. Trail Making Test A & B 
7. Category Fluency (Semantic) Animals 
If there is insufficient time for the entire test battery, assessment can be shortened to 10-15 
minutes by examining verbal fluency (FAS, animals, see Figures 5 and 6), speed and 
executive functions (Symbol Digit, Stroop Test, TMT A & B) (Lezak et al., 2004; Strauss et al., 
2006). The full test battery is suitable for annual examination which track the mutation 
carrier's functional levels for employment and holding a driver's licence while in the 
prodromal phase. Learning effects of the UHDRS are minimal, except for the HVLT, which 
is available in six parallel versions (Beglinger et al., 2010; Brandt & Benedict, 2001). The 
HVLT consists of an episodic memory task with 12 words, with four words from each of 
three semantic categories. The parallel versions avoid learning effects in annual patient 
evaluations (Solomon et al., 2007; Woods et al., 2005).  
7.2 In-depth clinical neurological/neuropsychological examination 
In recent years, quantified neurological examinations (Folstein et al., 1983) have been 
supplemented and/or replaced by the Unified Huntington's Disease Rating Scale (UHDRS) 
for examination of motor functions in HD (Huntington Study Group, 1996). The Total 
Functional Capacity (TFC) scale is used internationally as a neurological functional scale 
that includes areas such as activities of daily living (ADL), occupational activities, financial 
management, living chores and care needs (Paulsen et al., 2010; Shoulson & Fahn, 1979). The 
total functional scale (0-13) score correlates highly with cognitive and motor impairments 
(Kremer, 2002). Great care is needed in the selection of neuropsychological test battery 
instruments, in order to ensure high sensitivity in detecting prodromal evidence of HD. 
Although there are now a number of published studies of cognitive impairment in 
prodromal HD, it has not yet been established whether there is a characteristic pattern of 
impaired cognitive function prior to the onset of the motor symptoms of HD. Two studies 
report a pattern of prodromal cognitive function and intelligence as measured by the Wechsler 
Adult Intelligence Scale (Wechsler, 1997), with Robins Wahlin reporting significant differences 
in functioning across the various WAIS-R subtests and Verbal, Performance and Full Scale 
IQ scores (see Figure 7 and 8) (de Boo et al., 1997; Robins Wahlin et al., 2010). 
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Fig. 5. Phonemic fluency as measured by the letters FAS in a Swedish sample of prodromal 
mutation carriers (n=29) and noncarriers (n=34) of HD (Larsson et al., 2008). 
 
 
Fig. 6. Semantic fluency as measured by the categories Animals, Fruits and Vegetables in a 
Swedish sample of prodromal mutation carriers (n=29) and noncarriers (n=34) of HD 
(Larsson et al., 2008). 
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Fig. 7. Weighted scores in the WAIS-R Verbal subtests in noncarriers (HD noncarriers, 
n=35), mutation carriers with 12 or more years to disease onset (HD DISTANT onset, n=15) 
and mutation carriers with less than 12 years to disease onset (HD CLOSE onset, n=15) for 
Huntington’s Disease (Robins Wahlin et al., 2010).  
 
 
Fig. 8. Weighted scores in the WAIS-R Performance subtests in noncarriers (HD noncarriers, 
n=35), mutation carriers with 12 or more years to disease onset (HD DISTANT onset, n=15) 
and mutation carriers with less than 12 years to disease onset (HD CLOSE onset, n=15) for 
Huntington’s Disease (Robins Wahlin et al., 2010).  
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7.3 Comprehensive psychometrics 
Neuropsychological testing is recommended every two years to identify early signs of 
cognitive disabilities in mutation carriers, with the test battery covering a wide range of 
cognitive functions. Verbal fluency must always be included and it is worth noting that 
phonemic fluency shows earlier reductions than semantic fluency (Larsson et al., 2008). This 
pattern indicates that the frontal functions are involved at an early stage in disease progress. 
The most common categories of semantic fluency are animals, professions, vegetables and 
means of transport, for which there are normative data (Strauss et al., 2006). Numerous tests 
are available to test Episodic Memory with both verbal (words, sentences) and non-verbal 
materials (faces, objects, spatial positions and geometric shapes) (Lezak et al., 2004; Strauss 
et al., 2006). Furthermore, both free recall and recognition tests can be administered directly 
after the learning opportunity and also after longer time intervals (Lezak et al., 2004). Tests 
of Vocabulary and Information (WAIS, Figure 7) are useful to study Semantic memory 
(Wechsler, 1997). Short-term memory can be examined in both verbal (Digit Span, see Figure 
7) and non-verbal (Corsi Block) tasks, while procedural memory can be studied with the 
Tower of London or Tower of Hanoi test (Figure 2). Appropriate tests for executive functions 
and psychomotor speed are the Stroop and the TMT A & B. The Wisconsin Card Sorting Test is 
less appropriate because it is time-consuming and has been shown to be not sensitive to HD 
(Grant & Berg, 1948; Milner, 1963). Block Design (WAIS, Figure 8), the Rey-Osterrieth Complex 
Figure test (ROCF, Figure 3 and 4) (Osterrieth, 1944; Rey, 1941)] and Mental Rotations 
(Vanderberg, 1971) are sensitive for visuospatial features (Robins Wahlin et al., 2007). Mental 
tempo is best noted during the neuropsychological investigations. Digit Symbol (WAIS, Figure 
8) and Dots (Ekberg & Hane, 1984) or equivalent, are particularly straightforward to 
administer and provide reliable measures of psychomotor slowing in HD. 
8. Genetic testing 
8.1 Guidelines for genetic testing 
The disclosure of the huntingtin gene mutation and trinucleotide CAG repeats in HD has 
provided new opportunities to determine diagnosis prior to the onset of motor symptoms. 
At risk persons may choose to find out whether they have inherited the mutation for the 
disease. International guidelines for genetic testing are (a) 18 years or older, (b) 50% risk of 
HD, (c) 25% risk of HD if parent is deceased or if the parent with a 50% risk is participating 
in the genetic test process (Broholm et al., 1994; Nance et al., 2003; World Federation of 
Neurology: Research Committee. Research Group on Huntington's chorea, 1989). The most 
common reasons for genetic testing are to obtain certainty for genetic status (77%), general 
planning for the future and family (38%), or in the interests of the children (Robins Wahlin 
et al., 2000). Information about genetic testing for HD is given in the clinical genetics 
department (or equivalent) in larger hospitals or specialized centers for HD. Prenatal 
diagnosis can be provided when the parents are considering termination of the pregnancy if 
the result shows that the fetus carries the mutation (Decruyenaere et al., 2007; Simpson & 
Harper, 2001). In some countries prenatal diagnosis, including IVF, is covered by public 
health insurance. However, approximately 35% of couples decide not to have children after 
undertaking genetic testing (Decruyenaere et al., 2007). In practice, however, only a small 
minority of at risk individuals elects to undergo genetic testing for HD (Harper et al., 2000; 
Robins Wahlin et al., 2000). 
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8.2 Imaging studies in HD and prodromal HD 
Neuroimaging studies such as MRI, CT, SPECT and PET provide extra support for 
prodromal and manifest diagnosis of HD and are also valuable tools for studying disease 
progression (Antonini et al., 1996; Aylward, 2007; Montoya et al., 2006b; Paulsen, 2010; 
Paulsen et al., 2004). Volume of basal ganglia structures is reduced long before 
neuropsychological deficiencies can be demonstrated (Aylward et al., 1994). Recent MRI 
studies indicate that atrophy begins in the caudate nucleus approximately 11 years before 
clinical disease debut (Aylward et al., 2004). The putamen atrophies 9 years before manifest 
HD, followed by the cortico-striato-thalamocortical network and the frontal lobes which are 
affected later in the disease process (Paulsen, 2010). 
 
Fig. 9. MRI scan showing atrophy of the brain in Huntington’s Disease (courtesy of Joakim 
Tedroff and Mouna Esmaeilzadeh). 
Volumetric MRI data also demonstrate associations with cognitive impairments. The 
volume of the caudate nucleus and putamen has a strong relationship with decline in 
executive functions. Cortical matter degenerates later (Paulsen, 2010). PET studies have 
shown that other factors that contribute to cognitive impairments in HD are reduced 
dopamine transporter (DAT) and dopamine receptor density (D1 and D2) in the caudate and 
the putamen due to cell death (Antonini et al., 1998; Bäckman et al., 1997; Feigin et al., 2007). 
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A functional MRI study has shown reduced blood-oxygen-level dependent (BOLD) activity in 
the left dorsolateral prefrontal cortex in preclinical HD mutation carriers (Wolf et al., 2011).  
8.3 Diagnostic significance 
Genetic testing in recent years has provided possibilities for early diagnosis of HD and it is 
assumed that as the testing becomes more widely available more at risk persons will seek 
this information (Harper et al., 2000). There is, however, minimal research into the impact of 
early diagnosis on persons who are at risk of developing HD (Robins Wahlin, 2007). Some of 
those undergoing genetic testing will already have mild cognitive impairment that might 
interfere with their ability to process the results of testing. More importantly, support 
services are still inadequate for people who learn early in adulthood that they will develop 
the disease 10-40 years later. Mutation carriers and family are very concerned about 
cognitive impairments and dementia, since symptoms in HD are multifaceted and it is 
difficult to specify exactly how cognitive decline will begin. The provision of factual 
information to mutation carriers and family might greatly reduce fear and anxiety. This 
information can be provided as feedback and support in the context of neuropsychological 
testing or during early visits to neurologists. Effective information about the cognitive 
deficits in the disease and a better understanding of the long prodromal phase and time 
course of HD would be beneficial for affected persons and family. Counseling and support 
may offer opportunities for the development of psychological compensation strategies 
(Robins Wahlin et al., 2010; Walsh, 1999). Evaluation of therapeutic interventions in HD 
requires a detailed neurological/neuropsychological examination based on cognitive and 
clinical methods. Blood workup is indicated to exclude other diseases affecting cognitive 
and everyday functions.  
9. Therapy and approach 
9.1 Treatment and care 
There are currently no effective, disease-modifying treatments for HD that might prevent its 
onset or slow down its progress (Mestre et al., 2009a, 2009b). In addition, the cognitive 
deficits found in HD are not susceptible to treatment. However, early detection of HD offers 
the potential in the future for prodromal diagnosis and early use of medication thereby 
possibly modifying its course. Treatment with donepezil (a cholinesterase inhibitor used 
primarily for symptomatic treatment in Alzheimer’s disease) has not been shown to 
improve motor performance or cognition in HD. Recent studies of treatment with an omega-
3 fatty acid (ethyl-eicosapentaenoic acid) and vitamin E did not show any beneficial effects 
(Feigin et al., 1996; Mestre et al., 2009a). However, the anti-dopaminergic, monoamine 
depleting agent, tetrabenazine, has been shown to be effective for the treatment of 
involuntary movements, but not for cognitive impairment or depression (Mestre et al., 
2009b). Symptomatic treatment with small doses of conventional neuroleptics (eg 
haloperidol) and atypical neuroleptics (eg olanzapine), can be used to treat psychotic 
symptoms and outbursts of aggression (Grove et al., 2000; Warby et al., 2007). Valproic acid 
has been used to treat myoclonic hyperkinesia and anti-parkinsonian medication can 
improve hypokinesis and rigidity. However, medication containing L-dopa can also 
increase the severity of choreatic movements. Benzodiazepines can reduce irritability and 
aggressiveness, as well as help with anxiety and sleep disorders. Neuropsychiatric problems 
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are treated in the usual way in the early stages of HD and such treatment can be of great 
benefit to the patient and the family in crisis. If the patient has delusions or hallucinations, 
contact with a psychiatrist is desirable, since treatment with neuroleptics is often complex. 
Side effects of neuroleptics may be unfavorable for the patient's cognition and this needs to 
be balanced in treatment. Depression should always be treated with medication and if 
possible with psychological therapy (such as cognitive behavior therapy) or regular clinical 
contact. Antiepileptic treatment is sometimes indicated, especially in juvenile HD.  
9.2 Clinical relevance and the approach to cognitive handicap 
Cognitive impairments in the prodromal phase of HD often reduce the working lives of 
mutation carriers and may even lead to major crises. The inertia, reduced psychomotor 
speed and cognitive decline, especially affecting attention and visuospatial cognition 
(Lawrence et al., 2000), may lead to issues with driving ability, thus causing social and 
mobility problems (Beglinger et al., 2010). A formal on-road driving assessment may be 
needed for those individuals with preclinical or clinical HD who dispute the clinician’s 
assessment of their likely driving ability. Through a thorough explanation of any cognitive 
disabilities, patients can understand and learn to adapt to the signs of approaching HD and 
to some extent compensate for the lost abilities. The development of the disease and 
cognitive disabilities requires annual follow-up as a minimum and compassionate measures 
in explaining, communicating and organizing supportive interventions, thus providing 
higher quality of life for struggling HD patients and families (Robins Wahlin et al., 1997).  
9.3 Specific approach for the mutation testing 
Choosing to have oneself tested should always be an individual choice and a thorough 
psychosocial evaluation should precede any such testing (Copley et al., 1995). A genetic test 
should never be imposed on an individual from any direction, especially as genetic 
discrimination against HD persons has been noted, although fortunately it is rare (Harper et 
al., 2004; Robins Wahlin, 2007). From 1993 onwards, direct mutation analysis has been used 
in most developed countries. This has allowed precise determination of an individual’s 
mutation status (Huntington’s Disease Collaborative Research Group, 1993). Prenatal 
diagnosis is available as well as prenatal exclusion testing if the prospective parents do not 
wish to know their genetic status (Warby et al., 2007). In some countries, as for instance in 
Belgium, prenatal exclusion testing using linkage analysis, pre-implantation genetic 
diagnosis exclusion testing and non-disclosure is available for at risk persons who want to 
exclude the mutation in their offspring but do not want to know their own carrier status 
(Decruyenaere et al., 2007). International consensus argues that children and young people 
under 18 years of age should not be tested for the HD mutation (Warby et al., 2007; 1989). 
Testing of minors is not ethically defensible because it removes the individual’s option to 
know or not know and may cause stigma within the family and society (Robins Wahlin, 
2007). It may also have serious educational and career consequences. 
9.4 Psychological support during genetic testing 
Since there is currently only limited symptomatic relief available, it is important for genetic 
counseling to occur both before and after disclosure of the results of genetic testing (Hedera, 
2001). Many patients feel ambivalent about knowing their risk status (Robins Wahlin, 2007). 
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The request is often for an immediate and quick investigation but frequently the at risk 
person does not attend the appointment, only to request a new one later. Changing the at 
risk status to mutation carrier or noncarrier status is a psychologically complex process, 
which should not be rushed. The candidate’s defence mechanisms and history of stress 
tolerance are key variables in this difficult process. After the discovery of their genetic status 
all candidates experience an immediate period of adaptation (Robins Wahlin, 2007). Many 
mutation carriers undergo a process of denial and a long period of significantly increased 
stress and depression, leading to long-term sick leave (Paulsen et al., 2010). Sometimes even 
those who find out that they do not carry the mutation have great difficulty adapting to 
their new genetic status, which may show itself in survivor guilt and even require therapy 
or counseling (Robins Wahlin et al., 1997). Psychosomatic symptoms of stress, anxiety and 
depression generally require symptomatic treatment and a therapy contact can be envisaged 
(Robins Wahlin et al., 2000).  
9.5 Support actions 
Personality changes and odd behavior associated with HD may also lead to relationship 
difficulties within the family (Close Kirkwood et al., 2002b). Catastrophic reactions to the 
cognitive impairment that is integral to HD and other psychosocial crises require 
professional support for the whole family (Robins Wahlin, 2007). Psychological support is 
critical when HD is complicated by depression and suicidal thoughts (Paulsen et al., 2005b; 
Robins Wahlin et al., 2000). Since HD has major consequences for the entire family, the 
therapeutic team needs to look beyond the individual patient. Psychological and social care 
planning can be adapted according to the different phases of illness seen in HD (Walker, 
2007). Different stages require varying degrees of assistance from psychiatrists, neurologists, 
social workers, guardians, dietitians, speech therapists, dental hygienists, physiotherapists, 
occupational therapists or clinical psychologists (Paulsen et al., 2005a). In the later stages of 
the illness, the HD patient often has difficulty eating, swallowing and managing their 
personal hygiene. Incontinence and balance problems make the patient dependent on total 
care (Warby et al., 2007; World Federation of Neurology: Research Committee. Research 
Group on Huntington's chorea, 1989). Management of basic ADL functions requires a 
personal carer in the affected family or nursing home, as the ADL management becomes 
increasingly important in the late HD stages. As family members witness severe cognitive 
decline in the affected person, their own predisposition to the mutation constitutes an 
additional strain. Siblings, children and grandchildren often becomes isolated from the rest 
of society and need additional support (Dewhurst et al., 1970). 
9.6 Diagnostic significance and cognitive testing 
Genetic testing for HD has in recent years provided opportunities for early diagnosis and 
evidence to date suggests that demand for genetic testing will increase in the future. 
However, knowledge is still inadequate about the psychological and physical impact of 
early diagnostics on people who are at risk of HD and those who learn that they will 
develop the disease. Family members and mutation carriers are often concerned about 
cognitive impairments and dementia. As the signs and symptoms in HD are multifaceted 
and clinicians cannot specify how and when the early indications will show, provision of 
factual information to carrier and family will greatly reduce fear and anxiety. This 
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information to the patient can be provided by means of feedback and support in the 
context of neuropsychological testing by a psychologist or during medical visits. 
Diagnostic information about the symptomatic and cognitive profile provides the best 
understanding of the disease to the carrier and family. To evaluate therapeutic 
interventions requires a detailed neurological/neuropsychological examination based on 
cognitive, clinical and sometimes even experimental methods. Significant progress in 
understanding cognition in prodromal HD has reinforced the need for HD to be viewed 
as both a cognitive and motor disease. Cognition needs to be viewed as a component of 
quality of life and this recognition by clinicians will aid in the treatment of the long 
prodromal stages of the disease. 
9.7 Future directions 
HD is an uncommon but devastating condition for which there is currently no effective 
disease-modifying treatment. Symptomatic treatments are only modestly effective for some 
manifestations of the illness. Subtle cognitive impairment commences well before motor 
manifestations in many patients, complicating social and occupational functioning. 
Dementia is inevitable if the person with HD lives long enough. Because of the autosomal 
dominant pattern of HD inheritance, the ability to definitively identify mutation carriers and 
the availability of mouse models with various phenotypes, the future of HD research should 
be positive. Clinical trials of putative disease-modifying treatments in preclinical HD 
mutation carriers are needed. Such trials will need to assess HD carriers serially with both 
neuropsychological and neuroimaging tests, as well as other more specific biomarkers (Weir 
et al., 2011). Public and philanthropic funds will be needed for the development of therapies 
for HD as its low-prevalence status is unlikely to drive sufficient entrepreneurial interest. 
However, further research into the slowly progressive cognitive impairment found in 
people with HD might serve as a useful model for other neurodegenerative conditions with 
less certain etiological factors. 
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